公开(公告)号：US11857517B2

公开(公告)日：2024-01-02

申请号：US17887461

申请日：2022-08-14

申请人： NLC Pharma Ltd

发明人： Dorit Arad

IPC分类号： A61K31/122 ,  A61P31/14 ,  A61K9/00 ,  A61K9/127 ,  A61K9/20 ,  A61K9/28 ,  A61K9/48 ,  A61K31/198 ,  A61K31/222 ,  A61K31/381 ,  A61K31/40 ,  A61K31/422 ,  A61K31/433 ,  A61K31/454 ,  A61K31/513 ,  A61K31/536 ,  A61K36/30

CPC分类号： A61K31/122 ,  A61K9/0053 ,  A61K9/0095 ,  A61K9/127 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/2095 ,  A61K9/282 ,  A61K9/2833 ,  A61K9/4833 ,  A61K9/4858 ,  A61K9/4866 ,  A61K31/198 ,  A61K31/222 ,  A61K31/381 ,  A61K31/40 ,  A61K31/422 ,  A61K31/433 ,  A61K31/454 ,  A61K31/513 ,  A61K31/536 ,  A61K36/30 ,  A61P31/14 ,  A61K2236/51

摘要： Described herein are compounds of Formula I:




wherein R1-R6 are as described herein, for use in the treatment of a coronavirus infection; a method of inhibiting a coronavirus 3CL protease, by contacting the 3CL protease with a compound of Formula I; as well as methods pharmaceutical composition comprising a compound of Formula I and at least one phospholipid, wherein a weight ratio of the phospholipid(s) to the compound in the composition is in a range of from 10:1 to 1:10. Further described herein is a method of treating a coronavirus infection in a subject in need thereof, by administering to the subject at least one compound that exhibits at least two of: inhibition of an activity of a 3CL protease of the coronavirus; inhibition of inflammation in the subject; and inhibition of autophagy in the subject.

公开(公告)号：US11844361B2

公开(公告)日：2023-12-19

申请号：US17226030

申请日：2021-04-08

申请人： WIPARO BIOMED LIMITED

发明人： David Schmidt

IPC分类号： A61K36/06 ,  A23G1/48 ,  A61K36/185 ,  A61K9/00 ,  A23G1/46 ,  A61K36/15 ,  A61K9/20 ,  A23G1/42

CPC分类号： A23G1/48 ,  A23G1/426 ,  A23G1/46 ,  A61K9/0056 ,  A61K9/2018 ,  A61K36/06 ,  A61K36/15 ,  A61K36/185

摘要： A composition for human consumption that combines various ingredients that boost stem cell activity. Illustrative ingredients may for example include high cacao content chocolate, medicinal mushroom extracts, substances containing or promoting DHEA, pine bark extract to convert arginine from cacao into nitric oxide to improve circulation. DHEA boosting substances may include truffle powder and/or pine pollen. An illustrative composition may have about 75% chocolate by weight, with cacao content of 73% or more, at least 10% truffle powder or pine pollen, at least 10% medicinal mushroom extracts, the remainder pine bark extract. The composition may be formulated into sublingual tablets of about 1 gram, and daily consumption may for example consist of 5 tablets for 5 grams total. Includes a method of supporting cardiovascular health, improving sexual performance and sexual health, and improving athletic performance by administering a therapeutic amount of the compound to a subject.

公开(公告)号：US20230399331A1

公开(公告)日：2023-12-14

申请号：US18209674

申请日：2023-06-14

申请人： Incyte Corporation

发明人： Zhongjiang Jia ,  Weiguo Liu ,  Pingli Liu ,  David Meloni ,  Yongchun Pan ,  Jiacheng Zhou ,  Travis Houston

IPC分类号： C07D487/04 ,  A61K9/06 ,  A61K47/10 ,  A61K47/14 ,  A61K47/36 ,  A61K47/06 ,  A61K47/44 ,  A61K47/32 ,  A61K47/18 ,  A61K47/26 ,  A61K9/107 ,  A61K9/20

CPC分类号： C07D487/04 ,  A61K9/06 ,  A61K47/10 ,  A61K47/14 ,  A61K47/36 ,  A61K47/06 ,  A61K47/44 ,  A61K47/32 ,  A61K47/183 ,  A61K47/26 ,  A61K9/107 ,  A61K9/2054 ,  A61K9/2018 ,  A61K9/2009 ,  A61K9/2013 ,  C07B2200/13

摘要： The present disclosure is related to solid forms of ruxolitinib di-hydrate and ruxolitinib free base, process of preparing the same, and compositions comprising the same.

公开(公告)号：US20230399319A1

公开(公告)日：2023-12-14

申请号：US17788916

申请日：2020-12-25

申请人： Japan Tobacco Inc.

发明人： Yusuke OHBA ,  Takayuki FURUKAWA ,  Kaoru ADACHI ,  Tatsuya NISHIMARU ,  Kentaro SAKURAI ,  Ritsuki MASUO ,  Tasuku INAMI

IPC分类号： C07D413/12 ,  C07D263/48 ,  C07D487/08 ,  C07D498/08 ,  C07D491/107 ,  C07D498/10 ,  C07D491/04 ,  C07D487/04 ,  A61K9/48 ,  A61K9/20

CPC分类号： C07D413/12 ,  A61K9/2013 ,  C07D487/08 ,  C07D498/08 ,  C07D491/107 ,  C07D498/10 ,  C07D491/04 ,  C07D487/04 ,  A61K9/4866 ,  A61K9/4858 ,  A61K9/4825 ,  A61K9/2018 ,  A61K9/2059 ,  A61K9/2054 ,  C07D263/48

摘要： An acylsulfamide compound, or a pharmaceutically acceptable salt thereof, having NLRP3 inflammasome inhibitory activity, a pharmaceutical composition comprising the same, and their medical use, etc., are provided.
A compound of Formula [Ia]:






or a pharmaceutically acceptable salt thereof, wherein

a partial structure:












is:












Ring Cy is an optionally substituted heteroaryl or phenyl;
RDy and REy are each independently hydrogen, optionally substituted C1-6 alkyl, optionally substituted C1-4 haloalkyl, optionally substituted C3-6 cycloalkyl, optionally substituted heterocycloalkyl, or optionally substituted heteroaryl, or alternatively, RDy and REy may combine together with the nitrogen atom to which they attach to form heterocycloalkyl, etc.

公开(公告)号：US20230381188A1

公开(公告)日：2023-11-30

申请号：US18230693

申请日：2023-08-07

申请人： Boehringer Ingelheim International GmbH

发明人： Thomas MEINICKE ,  Maximilian VON EYNATTEN

IPC分类号： A61K31/522 ,  A61K9/20 ,  A61K9/00 ,  A61K31/155 ,  A61K45/06

CPC分类号： A61K31/522 ,  A61K9/2018 ,  A61K9/0053 ,  A61K31/50 ,  A61K31/155 ,  A61K45/06 ,  A61K9/00 ,  A61K9/20

摘要： The present invention relates to a certain DPP-4 inhibitor for use in combination with metformin in CKD patients.

公开(公告)号：US11826472B2

公开(公告)日：2023-11-28

申请号：US18143927

申请日：2023-05-05

申请人： PURDUE PHARMA L.P. ,  PURDUE PHARMACEUTICALS L.P.

发明人： William H. McKenna ,  Richard O. Mannion ,  Edward P. O'Donnell ,  Haiyong H. Huang

IPC分类号： A61K9/28 ,  A61K9/20 ,  A61K9/16 ,  A61J3/06 ,  A61K9/00 ,  A61K31/485 ,  A61K47/34 ,  A61K9/24 ,  A61K45/06 ,  A61K47/10 ,  A61J3/10 ,  B29C43/00 ,  A61J3/00 ,  B29C37/00 ,  B29C43/52 ,  B29B7/88 ,  B29C35/04 ,  B29B7/02 ,  B29C35/16 ,  B29C43/02 ,  B29C71/00 ,  B29K71/00 ,  B29K105/00 ,  B29L31/00

CPC分类号： A61K9/28 ,  A61J3/005 ,  A61J3/06 ,  A61J3/10 ,  A61K9/0002 ,  A61K9/0053 ,  A61K9/1641 ,  A61K9/209 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2095 ,  A61K9/284 ,  A61K9/2853 ,  A61K9/2866 ,  A61K9/2893 ,  A61K31/485 ,  A61K45/06 ,  A61K47/10 ,  A61K47/34 ,  B29B7/02 ,  B29B7/88 ,  B29C35/045 ,  B29C35/16 ,  B29C37/0025 ,  B29C43/003 ,  B29C43/02 ,  B29C43/52 ,  B29C71/00 ,  B29C71/009 ,  A61K9/2072 ,  B29C2035/046 ,  B29C2035/1658 ,  B29K2071/02 ,  B29K2105/0035 ,  B29K2105/251 ,  B29K2995/0088 ,  B29L2031/753

摘要： The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

公开(公告)号：US20230364013A1

公开(公告)日：2023-11-16

申请号：US18030541

申请日：2021-10-07

申请人： Catalent U.K. Swindon Zydis Limited

发明人： Leon Paul GROTHER ,  Nicholas Walker BARRAS ,  Philip AXE ,  Michael John HUTCHINSON

IPC分类号： A61K9/00 ,  A61K31/137 ,  A61K9/20

CPC分类号： A61K9/0056 ,  A61K31/137 ,  A61K9/2063 ,  A61K9/2009 ,  A61K9/2018 ,  A61K9/2095

摘要： The present disclosure is directed to oral dosage forms and processes for producing the oral dosage forms. The dosage forms include an Epinephrine hormone or pharmaceutically acceptable salt or solvate thereof, an antioxidant, and a chelating agent. The antioxidant can be sodium metabisulfate and the chelating agent can be edetate disodium (“EDTA”).

公开(公告)号：US11813275B2

公开(公告)日：2023-11-14

申请号：US17381498

申请日：2021-07-21

申请人： Boehringer Ingelheim International GmbH

发明人： Uli Christian Broedl ,  Odd-Erik Johansen ,  Gabriel Woojai Kim ,  Eric Williams Mayoux ,  Afshin Salsali ,  Nima Soleymanlou ,  Maximilian von Eynatten ,  Hans-Juergen Woerle ,  David Z.I. Cherney ,  Bruce A. Perkins ,  Andreas Daiber ,  Thomas Muenzel

IPC分类号： A61K31/7048 ,  A61K9/20 ,  A61K9/28

CPC分类号： A61K31/7048 ,  A61K9/2018 ,  A61K9/2866

摘要： The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.

公开(公告)号：US20230355578A1

公开(公告)日：2023-11-09

申请号：US18028625

申请日：2020-09-29

申请人： LABORATORIOS SILANES S.A. DE C.V.

发明人： Paola Yazmín OLLERVIDES RUBIO ,  Jorge Alejandro GONZÁLEZ CANUDAS ,  Sixto Serafín ESPINOZA LEÓN ,  Claudia Delfina FARFÁN SALAZAR

IPC分类号： A61K31/40 ,  A61K31/216 ,  A61K9/20 ,  A61K9/28

CPC分类号： A61K31/40 ,  A61K31/216 ,  A61K9/2095 ,  A61K9/2031 ,  A61K9/2018 ,  A61K9/2009 ,  A61K9/2059 ,  A61K9/2013 ,  A61K9/284

摘要： A combination, in a single dosage form, the active principles, atorvastatin and fenofibrate, which represents a set of important technological challenges due to the physicochemical properties and the difference in dosage to ensure obtaining a stable product in the treatment of hyperlipidemia and the prevention of cardiovascular diseases.

公开(公告)号：US20230346779A1

公开(公告)日：2023-11-02

申请号：US18020980

申请日：2021-08-13

申请人： Newave Pharmaceutical Inc.

发明人： Yi Chen

IPC分类号： A61K31/4985 ,  A61K9/20 ,  A61K31/497

CPC分类号： A61K31/4985 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054 ,  A61K31/497

摘要： Provided herewith are pharmaceutical tablet compositions comprising an organic acid (such as fumaric acid) and a compound of Formula (I), or an N-oxide thereof, solvate, polymorph, tautomer, stereoisomer, an isotopic form, or a prodrug of said compound of Formula (I) or N-oxide thereof: wherein the compound of Formula (I) is an inhibitor of Bruton's tyrosine kinase.